Cancer Treatment Reviews
Volume 31, Issue 8 , Pages 618-627 , December 2005

Taxanes in the treatment of early breast cancer

References 

  1. Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol. 1999;17(11):3403–3411
  2. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol. 2000;18(4):724–733
  3. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol. 1999;17(8):2341–2354
  4. Bishop JF, Dewar J, Toner GC, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol. 1999;17(8):2355–2364
  5. Figgitt DP, Wiseman LR. Docetaxel: an update of its use in advanced breast cancer. Drugs. 2000;59(3):621–651
  6. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;352(9132):930–942.
  7. Henderson IC, Berry D, Demetri G, et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. In: Proceedings of the American Society of Clinical Oncology 1998, abstract 390.
  8. Piccart MJ, Klastersky J, Meunier F, Lagast H, VanLaethem Y, Weerts D. Taxanes in the adjuvant treatment of breast cancer: why not yet?. J Natl Cancer Inst Monogr. 2001;0(30):88–95
  9. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976–983
  10. Mamounas EP. Evaluating the use of paclitaxel following doxorubicin/cyclophosphamide in patients with breast cancer and positive axillary nodes. In: Adjuvant therapy for breast cancer. NIH Consensus Statement, November 1–3, 2000.
  11. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotehrapy for node-positive breast cancer: results from NSABP B28. In: Proceedings of the American Society of Clinical Oncology 2003, abstract 12.
  12. Albain KS, Green SJ, Ravdin PM, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). In: Proceedings of the American Society of Clinical Oncology 2002, abstract 143.
  13. Thomas E, Buzdar A, Theriault R, et al. Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of prospective randomized clinical trial. In: Proceedings of the American Society of Clinical Oncology 2000, abstract 285.
  14. Buzdar AU, Singletary SE, Valero V, et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002;8(5):1073–1079
  15. Roché H, Fumoleau P, Spielmann M, et al. Five year analysis of the PACS01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. In: Proceedings of the San Antonio Breast Cancer Symposium, 2004, abstract 27.
  16. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–2313
  17. Gianni L, Baselga J, Eiermann W, et al. European Cooperative Trial in operable breast cancer (ECTO): improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. In: Proceedings of the American Society of Clinical Oncology 2005, abstract 513.
  18. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431–1439
  19. Fumoleau P, Bremond A, Kerbrat P, et al. Better outcome of premenopausal node-positive breast cancer patients treated with 6 cycles vs. 3 cycles of adjuvant chemotherapy:eight year follow-up results of FASG 01. In: Proceedings of the American Society of Clinical Oncology 1999, abstract 252.
  20. Martin M, Lluch A, Segui MA, et al. Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide for node-negative breast cancer: an interim safety analysis of the GEICAM 9805 study. In: Proceedings of the American Society of Oncology 2004, abstract 620.
  21. van ’t Veer LJ, Dai H, van de Vijver , et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–536
  22. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009
  23. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362(9381):362–369
  24. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer A. 1994;30(5):645–652
  25. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995;13(3):547–552
  26. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672–2685
  27. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17(2):460–469
  28. Ellis P, Smith I, Ashley S, et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol. 1998;16(1):107–114
  29. Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999;17(11):3412–3417
  30. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165–4174
  31. Bear HD, Anderson S, Smith RE, et al. A randomised trial comparing preoperative doxorubicin/cyclophosphamide to preoperative AC followed by preoperative docetaxel and to preoperative AC followed by postoperative docetaxel in patients with operable carcinoma of the breast: results of the NSABP B27 trial. In: Proceedings of the San Antonio Breast Cancer Symposium, 2004, abstract 26.
  32. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20(6):1456–1466
  33. Hutcheon AW, Heys SD, Sarkar TK, et al. Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. In: Proceedings of the San Antonio Breast Cancer Symposium 2003, abstract 11.
  34. Gianni L, Baselga J, Eiermann W, et al. First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy on loco-regional disease. In: Proceedings of the American Society of Clinical Oncology 2002, abstract 132.
  35. Untch M, Konecny G, Ditsch N, et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study. In: Proceedings of the American Society of Clinical Oncology 2002, abstract 133.
  36. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel followed by FAC in the neo-adjuvant setting provides improved pathological complete remission rates compared to standard paclitaxel followed by FAC therapy: preliminary results of an ongoing prospective randomized trial. In: Proceedings of the American Society of Clinical Oncology 2001, abstract 129.
  37. Hurley J, Doliny P, Silva O, et al. Neoadjuvant herceptin/taxotee/cisplatin in the treatment of locally advanced and inflammatory breast cancer. In: Proceedings of the American Society of Clinical Oncology 2002, abstract 196.
  38. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003;21(1):46–53
  39. Goldstein L, O’Neill A, Sparano E, et al. E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. In: Proceedings of the American Society of Clinical Oncology 2005, abstract 512.

PII: S0305-7372(05)00173-8

doi: 10.1016/j.ctrv.2005.09.005

Cancer Treatment Reviews
Volume 31, Issue 8 , Pages 618-627 , December 2005

Article Tools